Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Por:
Molina, JM, Gallant, J, Orkin, C, Negredo, E, Bhatti, L, Gathe, J, Van Landuyt, E, Lathouwers, E, Hufkens, V, Vanveggel, S and Opsomer, M
Publicada:
1 jul 2017
Resumen:
Filiaciones:
Molina, JM:
Univ Paris 07, Denis Diderot, Paris, France
Gallant, J:
Southwest CARE Ctr, Santa Fe, NM USA
Orkin, C:
Barts & Hlth NHS Trust, London, England
:
Germans Trias I Pujol Univ Hosp, Badalona, Spain
Bhatti, L:
AIDS Healthcare Fdn, Beverly Hills, CA USA
Gathe, J:
Therapeut Concepts, Houston, TX USA
Van Landuyt, E:
Janssen Pharmaceut NV, Beerse, Belgium
Lathouwers, E:
Janssen Pharmaceut NV, Beerse, Belgium
Hufkens, V:
Janssen Pharmaceut NV, Beerse, Belgium
Vanveggel, S:
Janssen Pharmaceut NV, Beerse, Belgium
Opsomer, M:
Janssen Pharmaceut NV, Beerse, Belgium
|